Related Experiment Video
Updated: Jul 12, 2026
07:27
The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
Published on: October 21, 2017
Angiogenesis in chronic liver disease.
Anjali D Amarapurkar1, Deepak N Amarapurkar, S Vibhav
1Department of Pathology, BYL Nair Charitable Hospital and TN Medical College, India.
Annals of Hepatology
|September 6, 2007
Summary
Angiogenesis, marked by CD34 and vascular endothelial growth factor (VEGF), is present in chronic liver disease and increases with fibrosis stage. Targeting VEGF may prevent disease progression.
Area of Science:
- Hepatology
- Oncology
- Pathology
Background:
- Chronic liver disease involves inflammation and fibrosis, where angiogenesis may impact prognosis.
- Interfering with angiogenesis presents a potential therapeutic target for managing liver disease progression.
Purpose of the Study:
- To evaluate CD34 and vascular endothelial growth factor (VEGF) as markers of angiogenesis in chronic liver disease.
- To correlate the expression of CD34 and VEGF with the stage of liver fibrosis.
Main Methods:
- Analysis of liver biopsies from 79 chronic liver disease patients and 21 hepatocellular carcinoma (HCC) cases.
- Immunohistochemical staining for CD34 and VEGF, compared with fibrosis staging and normal liver controls.
Main Results:
- Angiogenesis was observed in 45.5% of chronic liver disease cases; normal livers showed no CD34 or VEGF positivity.
- CD34 was positive in 85.7% of HCC cases. Angiogenesis markers increased with fibrosis stage (20.9% in stage 1/2 vs. 75% in stage 3/4).
- Vascular endothelial growth factor (VEGF) was more prevalent than CD34 in early fibrosis stages.
Conclusions:
- Angiogenesis is present in chronic liver disease and correlates with fibrosis progression.
- VEGF expression is common in early fibrosis stages, suggesting it as a potential therapeutic target.
- Inhibiting VEGF may be crucial for preventing the advancement of chronic liver disease.
More Related Videos
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
11:44Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice
Published on: March 24, 2015
Related Concept Videos
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:12Chronic Inflammation: Introduction
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
01:24Liver Regeneration
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...